The GLP-1 analog liraglutide, a modified human GLP-1(7–37) with a longer half-life29, is administered systemically in patients with type II diabetes (commercial name Victoza®) and obesity (commercial name Saxenda®). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.